Fig.1 OXA induced AD model in hIL4/hIL4R mice. (A) body weight (B) body weight change.
Fig.2 OXA induced AD model in hIL4/hIL4R mice. (A) gross observation on Day 21? (B) ear thickness (C) clinical score of skin.
Fig.3 OXA induced AD model in hIL4/hIL4R mice. (A) serum IgE (B) spleen weight.
Fig.4 OXA induced AD model in hIL4/hIL4R mice. (A) Pathology photos (B) Pathology score.
Fig.1 Body weight of hIL4/hIL4Ra mice treated with dupilumab. *P<0.05.
Fig.2 Dupilumab ameliorate overall atopic dermatitis activity in DNFB-induced AD Model. *P<0.05, **P<0.01, ***P<0.001.
Fig.3 Dupilumab treatment significantly reduced IgE levels in serum and scratching times.?(A) day10 serum IgE (B) day16 serum IgE (C) scratch times on Day 12 (D) scratch times on Day 14. *P<0.05, **P<0.01, ***P<0.001.
Fig.4 Dupilumab significantly mitigates inflammatory cell infiltration in lesioned skin on day 14. (A) dorsal image on day14; (B) Representative pathology images; (C) Inflammatory cell infiltration score; (D) neutrophils score; (E) eosinophils score; (F) epidermis thickness; (G) dermis thickness.?*P<0.05, **P<0.01, ***P<0.001.
請(qǐng)完整填寫訂購意向單,我們會(huì)在2個(gè)工作日內(nèi)與您聯(lián)系。